Brand Asset Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Brand Asset Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25	Closed	-$5K	–	340
2019 Q1	$5K	Buy	+25	New	+$4.62K	﹤0.01%	285
2018 Q4	–	Sell	-72	Closed	-$14K	–	267
2018 Q3	$14K	Buy	+72	New	+$12.8K	0.01%	197

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Brand Asset Management Group's VRTX Position: Q2 2019 in Review

Brand Asset Management Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 25 shares — an estimated $5K sold.

Brand Asset Management Group first reported a position in VRTX in Q3 2018 and held it in 2 quarters. The position peaked at $14K in Q3 2018. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Brand Asset Management Group reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Brand Asset Management Group sold 25 Vertex Pharmaceuticals shares in Q2 2019, an estimated $5K.
Brand Asset Management Group first reported a position in Vertex Pharmaceuticals in Q3 2018 and held it in 2 quarters.
Brand Asset Management Group's Vertex Pharmaceuticals position peaked at $14K in Q3 2018.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Brand Asset Management Group's 13F filing for Q2 2019, filed 24 Jul 2019.